EULAR 2022
The road of glucocorticoids in RA
high5immunology.tv | Rheumatology | EULAR 2022
EULAR 2022
The road of glucocorticoids in RA
EULAR 2022
Updated EULAR RA recommendations: does it change the…
EULAR 2022
Prevention of RA possible by treating very early?
Updated EULAR Recommendations RA, GLORIA
EULAR 2022
Rapid tapering of steroids - how quickly should we…
TREAT EARLIER
EULAR 2022
Interest of methotrexate before the emergence of RA
TREAT EARLIER
EULAR 2022
Does MTX have a disease modifying effect in patients…
EULAR 2022
The significance of depression and air pollution in…
EULAR 2022
HOT - Difficulties in treatment of RA
TREAT EARLIER
EULAR 2022
Double-blind placebo controlled trial of MTX in…
ORAL Survaillance
EULAR 2022
Risk of venous thromboembolic events in ORAL…
RA-BIODAM
EULAR 2022
Radiographic progression in RA patients in daily…
ORAL Surveillance
EULAR 2022
Analysis of baseline ORAL surveillance data: is it due…
ARIAA
EULAR 2022
Can early abatacept therapy in high-risk patients…
EULAR 2022
Betydning av depresjon og luftforurensning hos…
ORAL Survaillance
EULAR 2022
Riesgo de eventos tromboembolicos en el ORAL…
ARIAA
EULAR 2022
Frühzeitige Abatacept-Therapie bei Hochrisiko RA…
ORAL Surveillance
EULAR 2022
Liegt es an Vorgeschichte und oder Geographie?
TREAT EARLIER
EULAR 2022
Metotrexate en pacientes con artralgia inflamatoria en…
TREAT EARLIER
EULAR 2022
Har MTX en sykdomsmodifiserende effekt hos pasienter…
EULAR 2022
Abordaje de la artritis reumatoide difícil de tratar
EULAR 2022
MRT auch ohne Kontrastmittel bei RA einsetzbar
TREAT EARLIER
EULAR 2022
Interet du méthotrexate avant l´émergence de la PR
RA-BIODAM
EULAR 2022
Radiologische Progression ist unabhängig von…
EULAR 2022
New data on IL-17 inhibition and a 1st in class…
EULAR 2022
The (unmet) need for perspective biomarkers in SpA
EULAR 2022
Hot topic spine: axial diseases in SpA and suitable…
EULAR 2022
A new treatment for PsA
EULAR 2022
Every joint counts! Even patients with LJC should be…
ULTIMATE
EULAR 2022
Course of ultrasound-detected synovitis in PsA patients…
EULAR 2022
PsA is associated with a higher risk of hematological…
EULAR 2022
Revival of leflunomide - the combination with MTX
EULAR 2022
New therapies for PsA
EULAR 2022
Who has the best chance of being in prolonged remission…
Discover/Cosmos
EULAR 2022
Guselkumab "more safe" than Placebo
EULAR 2022
First in class: new molecule to inhibit IL-17A
EULAR 2022
Low rates of sustained remission in a real world…
Discover/Cosmos
EULAR 2022
Guselkumab "sicherer" als Plazebo
ULTIMATE
EULAR 2022
Verlauf von sonographischer Synovitis unter Secukinumab
EULAR 2022
Novità nel trattamento dell’Artrite Psoriasica
EULAR 2022
PsA mit einem höheren Risiko für hämatologische…
EULAR 2022
Jedes Gelenk zählt! Auch bei niedrigem Joint Count…
EULAR 2022
Qui a le plus de chance d´etre en rémission prolongee…
EULAR 2022
Geringe Raten an anhaltender Remission im Real Wold…
EULAR 2022
Revival von Leflunomid - in Kombination mit MTX
EULAR 2022
Neues Molekül zur Hemmung von IL-17A
SELECT-AXIS 2, BE MOBILE 2
EULAR 2022
New drugs in axSpA
EULAR 2022
New ASAS/EULAR axSpA recommendations
EULAR 2022
Rates of progression from non-radiographic to…
EULAR 2022
Artificial intelligence in axSpA
EULAR 2022
A deep dive review of axSpA
EULAR 2022
Nuevos recomendaciones ASAS/EULAR en EspAax
EULAR 2022
Inteligencia artificial en EspAax
EULAR 2022
Percentuale di progressione da forma non radiografica a…
SELECT-AXIS 2, BE MOBILE 2
EULAR 2022
Nuevos terapias en EspAax
EULAR 2022
Rivisitazione dell’impegno assiale dell'artrite…
EULAR 2022
Deucravacitinib for Lupus Erythematosus - Phase II…
AURORA-2
EULAR 2022
Voclosporin for Lupus Nephritis
EULAR 2022
TYK2-Inhibitor Deucravacitinib wirksam und verträglich
AURORA-2
EULAR 2022
Voclosporin bei Lupus Nephritis
EULAR 2022
Type of mRNA COVID-19 vaccine influences antibody…
EULAR 2022
Predictive severity factors of COVID-19 in R-IMID…
Nor-vaC study
EULAR 2022
Vaccination response against COVID-19 in patients with…
EULAR 2022
Vaccination in rheumatic diseases including COVID-19
EULAR 2022
Antikörperkinetik unter verschiedenen…
Nor-vaC study
EULAR 2022
Vaksine respons (COVID-19) hos pasienter med…
EULAR 2022
GM-CSF is increased in patients with AS and persists…
EULAR 2022
I livelli di GM-CSF sono incrementati nei pazienti con…
EULAR 2022
Management of calcific tendonitis by BARBOTAGE
EULAR 2022
New developments in the field of osteoarthristis
COMPACT
EULAR 2022
Real-world data of an etanercept biosimilar (GP2015) in…
EULAR 2022
The microbiota to predict the response to the treatment…
EULAR 2022
Pain - challenges in clinical practice
EULAR 2022
Link between biomechanical stretch and synovial…
EULAR 2022
Legame tra stress biomeccanico e infiammazione…
EULAR 2022
Le microbiote pour prédire la réponse au traitement du…
Für den erfolgreichen Abschluss der Fortbildungsmodule ist die korrekte (mind. 70%) Beantwortung der Lernerfolgskontrolle für das jeweilige Modul verpflichtend.
Jetzt gleich den Fragebogen ausfüllen!